<DOC>
	<DOCNO>NCT00659750</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy ciclesonide apply nasal spray daily patient PAR . The secondary objective evaluate Quality-of-Life safety .</brief_summary>
	<brief_title>To Assess Safety Efficacy Ciclesonide Applied Nasal Spray Treatment Perennial Allergic Rhinitis ( BY9010/M1-402 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . Male female 12 year old . 2 . General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk trial . 3 . A history PAR relevant perennial allergen minimum two year immediately precede study.The PAR must sufficient severity require treatment ( continuous intermittent ) past investigator 's judgment , expect require treatment throughout entire study period . 4 . A demonstrated sensitivity least one allergen know induce PAR standard prick test . A positive test define wheal diameter least 3 mm large control wheal prick test . Documentation positive result 12 month prior screen acceptable . Additionally , patient expect exposed PAR allergen he/she test positive via skin prick test duration study . 5 . Female childbearing potential currently take continue use medically reliable method contraception entire study duration ( e.g . oral , injectable , transcutaneous implantable contraceptive intrauterine device doublebarrier protection ) . Women childbearing potential , less 1 year postmenopausal , require negative serum pregnancy test Screening Visit ( B0 ) well last ontreatment visit ( T6 ) . 6 . Capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent compliance study requirement ( visit , record keep , etc ) . 1 . Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period 30 day follow study period . 2 . History physical finding nasal pathology , include nasal polyp ( within last 60 day ) clinically significant respiratory tract malformation , recent nasal biopsy ( within last 60 day ) , nasal trauma , surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day ) . 3 . Participation investigational drug trial within 30 day precede Screening Visit . 4 . A known hypersensitivity corticosteroid excipients formulation . 5 . History respiratory infection disorder [ include , limited bronchitis , pneumonia , common cold , acute chronic sinusitis , flu , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening Visit , development respiratory infection Baseline Period . 6 . History alcohol drug abuse within precede two year . 7 . History positive test HIV , hepatitis B hepatitis C. 8 . Active asthma require treatment inhale systemic corticosteroid and/or routine use bagonists ; intermittent use bagonists acceptable . 9 . Use prohibit concomitant medication within prescribe ( per protocol ) time since last dose period prior Screening Visit ( B0 ) entire treatment duration . 10 . Use antibiotic therapy acute condition within 14 day prior Screening Visit ( B0 ) . Low dos antibiotic take prophylaxis permitted therapy start prior Screening Visit AND expect continue throughout trial . 11 . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit AND use stable ( maintenance ) dose ( 30 day ) may consider inclusion . 12 . Previous participation intranasal ciclesonide study . 13 . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit ( B0 ) . 14 . Patients allergic seasonal aeroallergen , e.g . tree , grass weed , seasonal exacerbation anticipate occuror occurringduring study . 15 . Exposure systemic corticosteroid indication , chronic intermittent ( e.g . : contact dermatitis ) , past 2 month , presence underlying condition reasonably expect require treatment corticosteroid course study . 16 . Use topical corticosteroid concentration excess 1 % hydrocortisone dermatological condition past 1 month , presence underlying condition reasonably expect require treatment preparation course study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Perennial Allergic Rhinitis</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>PAR</keyword>
</DOC>